The big Covid-19 trials still to report
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
2020 wins top of the froths for biotech stocks
It's official: dramatic share price jumps in response to clinical data have become more common.
Scanning the horizon for future Covid-19 treatments
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
Synairgen joins the 2020 coronavirus winners club
A small trial of inhaled interferon marks a 30-fold increase in Synairgen stock since January, but the endpoints warrant scrutiny.
Hope replaces hype for coronavirus stocks
Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.
A Covid-19 treatment plan slowly emerges
Antivirals, anti-interleukins and vaccines take centre stage in clinical trial efforts to tackle the coronavirus pandemic.
